⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APGE News
Apogee Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
APGE
Form 8-K
sec.gov
ABBV
APGE
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
prnewswire.com
ABBV
APGE
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
prnewswire.com
ABBV
APGE
Form 8-K
sec.gov
APGE
Apogee Therapeutics to Participate in Upcoming June Conferences
globenewswire.com
APGE
Form 8-K
sec.gov
APGE
Form 8-K
sec.gov
APGE
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
globenewswire.com
APGE
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
globenewswire.com
APGE